

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT3703344

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF SECURITY INTEREST

**CONVEYING PARTY DATA**

Name	Execution Date
CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS COLLATERAL AGENT	12/21/2015

**RECEIVING PARTY DATA**

<b>Name:</b>	X-CHEM, INC.
<b>Street Address:</b>	100 BEAVER STREET
<b>Internal Address:</b>	SUITE 101
<b>City:</b>	WALTHAM
<b>State/Country:</b>	MASSACHUSETTS
<b>Postal Code:</b>	02453

**PROPERTY NUMBERS Total: 15**

Property Type	Number
Application Number:	61152508
Application Number:	13147910
Application Number:	61531820
Application Number:	61536929
Application Number:	14343306
Application Number:	61584593
Application Number:	61584569
Application Number:	61671406
Application Number:	14370854
Application Number:	61715116
Application Number:	14370879
Application Number:	61901899
Application Number:	62043275
Application Number:	14414326
Application Number:	62098037

**CORRESPONDENCE DATA**

Fax Number: (866)826-5420

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

PATENT

**Phone:** 301-638-0511  
**Email:** ipresearchplus@comcast.net  
**Correspondent Name:** IP RESEARCH PLUS, INC.  
**Address Line 1:** 21 TADCASTER CIRCLE  
**Address Line 2:** ATTN: PENELOPE J.A. AGODOA  
**Address Line 4:** WALDORF, MARYLAND 20602

**ATTORNEY DOCKET NUMBER:** CRS1-40847

**NAME OF SUBMITTER:** PENELOPE J.A. AGODOA

**SIGNATURE:** /pja/

**DATE SIGNED:** 01/20/2016

**Total Attachments: 4**

source=40847#page1.tif

source=40847#page2.tif

source=40847#page3.tif

source=40847#page4.tif

RELEASE OF PATENT SECURITY INTERESTS dated as of December 21, 2015 (this “Release”), by CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, as Collateral Agent (the “Collateral Agent”). Capitalized terms used herein and not otherwise defined shall have the meanings assigned to such terms in the Credit Agreement or the Security Agreement, as applicable, referred to below.

A. Reference is made to (i) the Credit Agreement dated as of August 18, 2015 (as amended, supplemented or otherwise modified from time to time, the “Credit Agreement”), among Jaguar Holding Company I (“Holdings”), Jaguar Holding Company II (the “Parent Borrower”), Pharmaceutical Product Development, LLC (the “Subsidiary Borrower” and, together with the Parent Borrower, the “Borrowers”), the lenders party thereto and the Collateral Agent, (ii) the Security Agreement dated as of August 18, 2015 (as amended, supplemented or otherwise modified from time to time, the “Security Agreement”), among the grantors listed therein and the Collateral Agent and (iii) the Intellectual Property Security Agreement dated as of August 18, 2015, among the grantors listed therein and the Collateral Agent (such documents set forth in clauses (i) through (iii), the “Security Documents”).

B. Pursuant to the Security Documents, the Persons listed on Schedule 1 hereto (the “Grantors”) granted to the Collateral Agent, for the benefit of the Secured Parties, a security interest in all right, title or interest of the Grantors in, among other things, (i) the patents and patent applications of the Grantors set forth on Schedule I hereto, (ii) all reissues, divisions, continuations, continuations-in-part, extensions, renewals and reexaminations of any of the foregoing, all rights in the foregoing provided by international treaties or conventions, all rights corresponding thereto throughout the world and all other rights of any kind whatsoever of the Grantors accruing thereunder or pertaining thereto, (iii) any and all claims for damages and injunctive relief for past, present and future infringement, dilution, misappropriation, violation, misuse or breach with respect to any of the foregoing, with the right, but not the obligation, to sue for and collect, or otherwise recover, such damages and (vi) any and all proceeds of, collateral for, income, royalties and other payments now or hereafter due and payable with respect to, and supporting obligations relating to, or arising from any of the foregoing (collectively, the “Patent Collateral”), which security interests were recorded with the United States Patent & Trademark Office on (i) September 2, 2015 at Reel/Frame 036528/0004.

C. The Borrowers hereby notify the Collateral Agent of the Subsidiary Borrower’s intention to sell, distribute or otherwise dispose of all of its equity interests in the Grantors. The Subsidiary Borrower’s sale, distribution or disposition of all of its equity interests in the Grantors is referred to herein as the “Spin-Off.”

Pursuant to Section 9.11 of the Credit Agreement and acting in reliance upon the certifications of the Borrowers set forth in the Release Letter, dated the date hereof, among the Borrowers and the Collateral Agent, the Collateral Agent does hereby

cancel, release, relinquish and discharge any and all security interests it has against the Patent Collateral, *provided, however,* that it is understood and agreed that such release, relinquish and discharge will be without recourse, representation or warranty of any kind (express or implied); *provided further,* that such release, relinquish and discharge is hereby expressly conditioned on the consummation of the Spin-Off. It is understood and agreed that if the Spin-Off is not consummated then all obligations of the Grantors in favor of the Collateral Agent and all security interests in the right, title or interests of the Patent Collateral, in each case, in effect immediately prior to the date hereof, shall remain in full force and effect.

The Collateral Agent authorizes the Subsidiary Borrower (or its designee) to make filings with the United States Patent and Trademark Office and other necessary filings, in each case at the expense of the Subsidiary Borrower, to evidence the release and termination of the Collateral Agent's security interests in the Patent Collateral.

THIS RELEASE SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK AND SHALL BE BINDING UPON THE COLLATERAL AGENT'S REPRESENTATIVES, SUCCESSORS, ASSIGNS AND TRANSFEREES.

[The remainder of this page intentionally left black]

IN WITNESS WHEREOF, the Administrative Agent has caused this Release to be duly executed as of the day and year first above written.

CREDIT SUISSE AG, CAYMAN ISLANDS  
BRANCH, as Administrative Agent,

By   
Name: MIKHAIL FAYBUSOVICH  
Title: AUTHORIZED SIGNATORY

By   
Name: Gregory Fantoni  
Title: Authorized Signatory

[Signature Page to Patent Release]

[[3972253]]

**PATENT**  
**REEL: 037534 FRAME: 0987**

Schedule I

Patents

**Patent Applications**

Owner	Application Number	Expiration Date
X-Chem, Inc.	61/152,508	N/A
X-Chem, Inc.	13/147,910	N/A
X-Chem, Inc.	61/531,820	N/A
X-Chem, Inc.	61/536,929	N/A
X-Chem, Inc.	14/343,306	N/A
X-Chem, Inc.	61/584,593	N/A
X-Chem, Inc.	61/584,569	N/A
X-Chem, Inc.	61/671,406	N/A
X-Chem, Inc.	14/370,854	N/A
X-Chem, Inc.	61/715,116	N/A
X-Chem, Inc.	14/370,879	N/A
X-Chem, Inc.	61/901,899	N/A
X-Chem, Inc.	62/043,275	N/A
X-Chem, Inc.	14/414,326	N/A
X-Chem, Inc.	62/098,037	N/A